Altered regulation of synthesis of acetohydroxy acid synthetase (AHAS) was previously reported in a mutant of Escherichia coli strain K-12. The mutant strain, growing in minimal medium, exhibits a partial growth limitation and derepression of AHAS, owing to deficient synthesis of isoleucine. The genetic lesion (ilvE503) causing the isoleucine limitation was shown to cause derepression of a valine-sensitive AHAS activity. The derepression effect of the ilvE503 mutation upon synthesis of AHAS was conclusively demonstrated by introducing both the ilvE503 allele and an altered AHAS (ilv-521) into the same cell. Evidence is presented that suggests the presence of multiple genetic regions for synthesis and control of the valine-sensitive AHAS activity.
In a previous report, spontaneous mutants of Escherichia coli strain K-12 were selected resistant to the isoleucine analogue, ketomycin (6) . One mutant, owing its resistance to a defective transaminase B (Fig. 1) , showed an effect by isoleucine upon regulation of synthesis of the presumed iluB gene product, a valine-sensitive acetohydroxy acid synthetase (AHAS). A two-to threefold derepression of the AHAS was observed with a limiting isoleucine signal in the absence of exogenous valine or leucine. Dwyer and Umbarger (4) reported that derepression of acetohydroxy acid synthetase in strain K-12 resulted from a valine or leucine limitation, but not isoleucine. A mutant deficient in isoleucyl-tRNA synthetase catalytic function was found to display an isoleucine limitation when growing in minimal medium (14) . In response to this limitation, threonine deaminase (TD) was derepressed but AHAS remained at normal levels in the absence of exogenous valine and/or leucine. Derepression of TD was expected as a normal response to the partial isoleucine limitation. Thus, before the work of Jackson and Umbarger (6) the view consistently held has been that isoleucine does not effect control of synthesis of valine-sensitive AHAS in strain K-12.
The ketomycin-resistant mutant strain CU2588, described in a previous report (6) , has been further examined to find an explanation for the novel effect of isoleucine on synthesis of AHAS in this mutant. It was necessary to consider the possibility of a second site mutation in strain CU2588 that might have altered the normal repression control of AHAS synthe-504 sis. Such a hypothetical second site mutation would have to lie within the ilv region or very near it, according to transduction linkage studies on strain CU2588. An obvious candidate was the postulated operator region, ilvP ( Fig. 1) , controlling synthesis of a valine-sensitive AHAS (11) . A mutation in ilvP could conceivably result in altered affinity for hypothetical repressor-corepressor complexes such that some form of isoleucine might be required to enable such complexes to regulate AHAS levels during growth in minimal medium. No other previously defined genetic region, within ilv or linked by transduction to ilv, would be expected to account for this effect on AHAS synthesis. In the absence of involvement of the ilvP region, one must consider that the observed regulatory effect by isoleucine on synthesis of AHAS is caused by the mutation that alters the transaminase B (ilvE503). It has been previously demonstrated that the ilvE503 mutation can signal "limiting isoleucine" (6) .
This report describes studies in which the ilvE503 locus is transduced into a strain constructed to contain an AHAS activity that is highly resistant to inhibition by valine. This modified AHAS activity is encoded by a locus unlinked by P1 transduction to the ilv region. The phenotype of this strain and other constructed control strains were characterized with respect to repression control of synthesis of the isoleucine-valine biosynthetic enzymes. The ilvE lesion was observed to cause an unlinked, insensitive AHAS activity to respond to repression control by isoleucine.
The isoleucine-valine biosynthetic pathway, the biosynthetic enzymes, and the genes coding for these enzymes are shown in Fig. 1 .
MATERIALS AND METHODS Organisms and conditions of cultivation. The strains used in this study are listed in Table 1 . In all experiments, the organisms were grown in a minimal salts-glucose medium (minimal medium; [2] ) containing supplements as indicated. Generation times were calculated from turbidimetric measurements of exponential growth with a Klett-Summerson colorimeter with a no. 42 filter.
Mutant selection and strain construction. Strain CU50 was selected as a spontaneous mutant resistant to a combination of 4-azaisoleucine (0.1 mM) and L-valine (1.2 mM) in the presence of L-leucine (0.4 mM). The general procedure of selection was reported in a previous paper (6) . Examination of biosynthetic enzyme activities revealed that the AHAS in strain CU50 (ilv-521) was modified in its response to inhibition by valine (1.0 mM). The phenotypic property of valine-resistant growth was used to screen constructed strains for the presence of the ilv-521 allele. For all strain constructions, the generalized transducing phage, P1, of E. coli was used to prepare lysates of the donor strain. Transductions were performed with either the method described by Lennox (8) or by Power (10) . Strain constructions that involved transfer of the ilvE5O3 lesion employed screening for positive excretion properties (Exc+). The method used for such screenings has been described (6) .
Preparation of crude extracts and assay of enzyme activity. Crude extracts for enzyme assays were prepared from exponential phase cultures of each strain examined. Preparations were made according to procedures previously described (13) , with the following modifications. (i) AHAS was assayed in crude extracts prepared with the buffer described by TD and AHAS specific activities were determined by procedures described elsewhere (12, 13) . Transaminase B specific activity was measured by a modification of the colorimetric procedure of Duggan and Wechsler (3) described in a previous paper (6) . Protein was measured by the biuret method (7) .
Chemicals. All commercially available chemicals used in this work were of reagent grade or of the highest purity otherwise obtainable. 4-Azaisoleucine was a gift from H. E. Umbarger.
RESULTS
Mutant selection and growth response. The prototrophic strain CU2001 was used as the parent for selection of a valine-resistant mutant, by the procedure described above. Valineresistant mutants were screened for amino acid excretion by an auxanographic method. Excreters of isoleucine and valine were examined for altered response of AHAS to inhibition by valine. Strain CU50 was found to contain AHAS activity highly resistant to inhibition by L-valine (1.0 mM).
The parent strain CU2001, the ketomycinresistant strain CU2588, and the valine-resistant strain CU50 were examined for growth characteristics. The mean generation time for each strain and growth conditions are shown in Table 2 . Strain CU2588, containing an altered transaminase B (ilvE503), grows with a mean generation time twice that of the parent strain. It is clear that the presence of 0.4 mM isoleucine restores the growth rate of strain CU2588 to a near-normal level, thus indicating that this strain undergoes an isoleucine limitation when growing in minimal medium. The generation time of strain CU50 (ilv-521) is approximately 35% greater than the parent strain but is not decreased by addition of isoleucine.
Comparative activities of branched-chain amino acid biosynthetic enzymes in parent and mutant strains. TD and transaminase B specific activities were measured as an index of function of the operon under the control of ilvO. AHAS was measured in order to assess the regulation presumably mediated through ilvP.
Specific activities, normalized relative to the parent strain CU2001, are shown in Table 3 . Clearly, strain CU2588 carries an alteration in transaminase B, as shown by the low relative specific activities. The specific activity of TD was nearly threefold elevated in strain CU2588 (as expected), owing to the demonstrated isoleucine limitation. Feedback inhibition by isoleucine is normal under all conditions, therefore these data are not shown. AHAS activity in strain CU2588 is three times that of strain CU2001, and inhibition by 1.0 mM valine (Table 4) appears to be normal. The presence of exogenous isoleucine during growth repressed synthesis of AHAS to normal levels in strain CU2588. bRelative specific activity = specific activity of mutant/specific activity of wild type. inhibition by valine at pH 8.0 the AHAS of CU50 is altered in its response to inhibition by valine over a pH range of 6.0 to 9.0 (Fig. 2) . The specific activity of AHAS at pH 7.0 in the valine-resistant mutant, CU50, is not decreased by valine, but at pH 6.0 the specific activity is sharply decreased by the presence of 1.0 mM valine. Activity in the wild-type strain appears to be highly sensitive to valine inhibition at all pH values. The mutation to valine-resistance is unlinked to ilvA by co-transduction. This lack of linkage was not expected according to the mapping results of Ramakrishnan and Adelberg (11) . We do observe, however, a low linkage (2%) to metE, suggesting that the structural gene involved lies on the ilv-distal side of metE.
Maximum inhibition of AHAS in the parent and mutant strains. Inhibition of AHAS activity in the presence of 1.0 mM valine was measured to compare the wild-type strain CU2001, the ilvE mutant CU2588, and the valine-resistant isolate CU50 (Table 4) . These data clearly show that AHAS activity in strain CU50 is markedly more resistant to inhibition by valine than in the other two strains. Further, AHAS activities in strains CU2001 and CU2588 have the same sensitivity to inhibition by valine.
Construction conceivably be co-transduced from strain CU2588 along with the ilvE503 mutation. To examine this possibility it was necessary to construct a strain carrying the ilvE503 mutation along with an identifiably different ilvP locus. Use of a feedback-modified AHAS from a separate strain was proposed as an indicator of the presence of an ilvP allele distinct from that in strain CU2588. This proposal rested upon the heretofore accepted concept that catalytic and feedback functions of AHAS were encoded by a single gene located adjacent to a repression recognition region. Thus, if an altered AHAS (ilv-521) of a separate strain required iosleucine for repression control of its synthesis in the presence of the ilvE503 allele, then a reasonable conclusion would be that the regulatory abnormalities observed in strain CU2588 were caused solely by the ilvE503 mutation. It would be highly unlikely that the ilv-521 mutation would be transduced without introducing an adjacent repression recognition region.
Strain CU16 was the recipient strain for both ilvE503 from strain CU2588 and ilv-521 from strain CU50. The ilvE503 mutation was introduced into CU16 by transduction from strain CU8506. The ilvE503 mutation was transduced as an unselected marker linked to rbs+. The constructed strain containing ilvE503 was labeled CU16523. The ilv-521 mutation was introduced into CU16 by transduction from strain CU50. The ilv-521 mutation was transduced by the simultaneous primary selection of metE+ and valine-resistance. The use of two markers in the primary selection was necessary to prevent the possibility of interference by spontaneous mutants arising resistant to valine, and to facilitate recovery of transductants having valine-resistance linked to metE. One, among several such constructed strains, is labeled CU16530. A third strain, CU16507, was constructed to contain both mutant alleles. This strain was constructed by transducing the ilv-521 mutation from strain CU50 into strain CU16523 (ilvE503, metE), in a primary double- (Table 5 ). The slow growth is attributable to the ilvE503 mutation in these strains. When each strain was grown in minimal medium supplemented with isoleucine, the mean generation time was restored to a value closer to that of the wild type.
Comparative activities of branched-chain amino acid biosynthetic enzymes in constructed strains. Specific activities of isoleucinevaline biosynthetic enzymes in the constructed strains are shown in Table 6 . Activities of all enzymes are expressed relative to those measured in the recipient strain, CU16, grown under identical conditions. The enzymatic phenotypes observed in strains CU16523 (ilvE503) and CU16530 (ilv-521) were comparable to those observed in the donor strains containing these mutations. Both TD and AHAS were derepressed when CU16523 was grown in minimal medium. Supplementation of the growth medium with isoleucine restored enzyme levels closely to those of the prototroph, CU16 metE+. Transaminase B activitv was very low, as expected, owing to the presence of the ilvE503 allele.
Strain CU16530 displayed phenotypic proper- ties comparable to those of strain CU50, the donor of the ilv-521 allele. AHAS activity was highly resistant to inhibition by valine (Table  7) , and was not repressed by isoleucine. The specific activity of AHAS in strain CU16530 was less than in the parent strain CU2001, but comparable to AHAS activity in strain CU16 metE+.
Both the ilvE503 and ilv-521 alleles were present in strain CU16507. Activity of transaminase B was barely detectable. AHAS activity was derepressed nearly 15-fold in cultures grown in minimal medium, and was repressible by isoleucine.
The presence of isoleucine in the growth medium did not reduce AHAS synthesis to the level observed in CU16 metE+. The reason for this probably involves effects of the ilv-521 allele in the original mutant isolate and the unaltered allele in the parent strain CU2001, compared with the same genetic region in the recipient strain CU16. The specific activity of AHAS in strain CU16 is one-third to one-half of that measured in strain CU2001. Thus, the repression of AHAS by isoleucine in strain CU16507 restores the specific activity to the normal level associated with the parent, strain CU2001, and in the mutant donor, strain CU2588.
Maximum inhibition of AHAS in constructed strains. Inhibition of AHAS activity in the presence of 1.0 mM valine was measured to indicate the presence or absence of the ilv-521 allele in constructed strains (Table 7) . Activity was determined in crude cell extracts from cultures grown in minimal medium, and in minimal medium supplemented with isoleucine. Clearly, the constructed strains CU16530 and CU16507 contain the ilv-521 phenotype of valine-insensitive AHAS activity. The inhibition of AHAS by valine was normal in the other constructed strains.
DISCUSSION
The current status of AHAS structural and regulatory gene locations is unclear. Evidence has been reported for a valine-resistant isozyme encoded by an ilvG gene that is postulated to lie near ilvE in Salmonella typhimurium ( [9] ; J.
Blatt, personal communication). The presence of two isozymes of AHAS, responding to different controls, has been clearly established for S. typhimurium and E. coli strain B (1, 9) . One isozyme is resistant to feedback inhibition by valine and derepresses in response to an isoleucine, valine, or leucine limitation. The other isozyme is sensitive to valine and responds to a signal of limiting valine or leucine. It has been suggested that the K-12 strain of E. coli contains a marginally functioning ilvG gene that is usually not transcribed (M. Freundlich, personal communication). Clearly, since the increased level of AHAS in ilvE503-carrying strains is inhibited by valine, increased synthesis of a normal ilvG gene product cannot account for the derepressed levels of AHAS resulting from the ilvE503 mutation. It therefore appears that the high level of AHAS results from overproduction of a valine-sensitive activity. Additionally, in the presence of the ilv-521 mutation, the derepressed AHAS activity was valine resistant. Thus, the ilvE503 mutation apparently participates in control of synthesis of the product of the ilv-521 locus. According to these results, the ilv-521 + allele would normally encode all or part of a valine-sensitive AHAS. If two distinct loci, ilvB and ilv-521, exist which both participate in expression of valine-sensi- Several explanations may be advanced to account for the apparent control of AHAS synthesis by isoleucine. It seems unlikely that a second site mutation in ilvP could account for this effect, unless ilvB encodes a subunit involved only in AHAS catalytic activity. By implication, then the ilv-521 allele would have to code for a regulatory subunit that interacts with the ilvB gene product. Therefore, a modified ilvP cannot be absolutely ruled out by these data. However, in order to invoke ilvP participation, it would be necessary to revise the generally accepted and disseminated concepts of AHAS control and synthesis.
A second possibility remains that a second site mutation is present in TD that alters only its postulated regulatory properties other than its catalytic or feedback functions.
A third possibility, favored by us, considers that a previously unrecognized control locus influences repression of AHAS synthesis. The control locus would either be part of or adjacent to ilvE. A mutation within ilvE or a terminal deletion extending from ilvE into an adjacent control locus could then conceivably cause an abnormal derepression of AHAS synthesis that would be partially corrected by recognizing some form of isoleucine as a corepressor. We favor the third possibility at the present time, owing to its simplicity. However, all three are being further tested. It is clear that, whatever the true nature of the control defect(s), isoleucine is involved in the modified regulation of AHAS synthesis. Conditions of mutant selection favored isolation of strains with a singlestep mutation, and the ilvE503 lesion altered regulation of synthesis of a valine-sensitive AHAS activity. These effects have not been observed in other transaminase B mutants. We therefore conclude that the regulatory effects of the ilvE503 mutation result from the altered synthesis of isoleucine and probably depend 
